"With this technology, we are getting closer to the goal of a widely clinically applicable liquid biopsy, where we can sample cancer cells by a simple blood draw and understand the genes that allow them to grow," said Dr. Antoni Ribas, a professor of medicine in the division of hematologyoncology, a Jonsson Cancer Center member and one of Tseng's key collaborators. "With the NanoVelcro chips, we will be able to better personalize treatments to patients by giving the right treatment to stop what makes that particular cancer grow."
Dr. Roger Lo, another key Tseng collaborator and an assistant professor in UCLA's department of medicine, division of dermatology, and department of molecular and medical pharmacology, was also optimistic about the new method.
"This scientific advancement being able to capture the melanoma cells in transit in the blood and then perform genetic analysis on them will in principle allow us to track the genomic evolution of melanoma under BRAF-inhibitor therapy and understand better the development of drug resistance," said Lo, who is also a member of the Jonsson Cancer Center.
|Contact: Shaun Mason|
University of California - Los Angeles